Karnataka to receive 13.90 lakh vaccine vials, will begin inoculation by 11 Jan, says state govt

-

Bengaluru: Karnataka health minister K Sudhakar on Friday said the state is expected to receive 13,90,000 vials of vaccine against COVID-19 in a day or two.

"The big good news for Karnataka is that I have received information from the Union Health Ministry that tomorrow or the day after probably we will be receiving 13,90,000 vials of vaccine for the state. It's a big happy news for all of us," Sudhakar said.

Speaking to reporters after visiting a private hospital, where vaccination dry run is being conducted, he said, the vaccination will be first administered to health care workers.

"We have registered 6.30 lakh healthcare professionals in Karnataka till date. Those who are left out, may be in some medical or dental colleges, we have requested them to register," he said adding that health workers will be followed by those with comorbidities, those above 60 years and those in other departments like Police and Revenue working against the
pandemic.

COVID-19 vaccination dry run is on at a total of 263 different health facilities across Karnataka on Friday.

It is being held in 24 district hospitals, 20 medical colleges, 43 taluk hospitals, 31 community health centres, 87 primary health centres, 30 urban primary health centres and 28 private facilities in the state.

The minister who visited some facilities, where the dry run is going on said, arrangements and preparedness were quite good, and the process is being followed as per the guidelines issued.

The first round of the dry run, an exercise for end-to-end testing of COVID-19 vaccination process was held in in five districts of Karnataka- Bengaluru (including BBMP), Belagavi, Kalburgi, Mysore and Shivamogga — on 2 December as per the government of India guidelines.



from Firstpost India Latest News https://ift.tt/3hRzMgM
Press Trust of India

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more